Background: Obesity associated hypertension is likely to be due to multiple mechanisms.
Introduction
Hypertension is a heterogeneous condition that is positively linked with obesity, although the causative factors for this association remain unclear (1) . Whilst the identification of the renin angiotensin system (RAS) has been documented within several tissues, its' presence in human adipose tissue may offer a potential link between obesity and hypertension (2) . Thus, RAS activation through the effector hormone, angiotensin II (ANG II), may alter vasoconstrictive and pro-thrombotic properties associated with cardiovascular disease (3) (4) (5) (6) .
We have previously shown that insulin upregulates the RAS system in human adipose tissue but the underlying mechanism for it was not clear (7) . TNFα is implicated in the development of insulin resistance because of the multitude of effects it exerts on insulin sensitive tissues. Numerous studies have demonstrated a positive correlation between TNFα and obesity, with regard to protein and mRNA expression in adipose tissue, as well as circulating levels of TNFα in obese and type 2 diabetic subjects (8, 9) . Furthermore, an association between elevated TNFα expression in adipose tissue and characteristics of insulin resistance has been described in obese and diabetic animal models, as well as humans (8, 10) .
TNFα can also regulate expression of AGT in hepatocytes as the AGT promoter contains a cytokine inducible enhancer known as the acute phase response element (APRE) (11) . TNFα induces transcription of AGT via the transcription factor NFκB, which is known to be involved in the production of numerous pro-inflammatory markers. This suggests a possible TNFα directed mechanism through which insulin may increase AGT and subsequent ANG II secretion.
Therefore, the aim of this study was to investigate the importance of the RAS in the pathogenesis of obesity associated hypertension both in vivo and in vitro. First, we established the importance of subcutaneous abdominal adipose tissue as a source of circulating ANG II and TNFα using an arterio-venous approach. As our previous studies had shown that insulin increases expression of the RAS, we examined the effect of insulin on the secretion of bradykinin to determine the net effect of insulin on the RAS pathway, thus delineating the potential hypertensive effect of insulin through its' effects on adipose tissue. Furthermore, we investigated whether insulin was regulating AGT through a TNFα directed mechanism by examining the effect of insulin and RSG on the secretion of TNFα from mature adipocytes. We then proceeded to determine the effect of TNFα on AGT protein expression and ANG II secretion, to elucidate a potential pathway for insulin leading to obesity associated hypertension through its' effects on adipose tissue. Lastly, because the insulin sensitiser, rosiglitazone (RSG), has been shown to lower blood pressure in animal models, patients with impaired glucose tolerance, T2DM patients and non-diabetic hypertensives (12-16), we investigated the effect of RSG on AGT expression and ANG II secretion in human adipocytes.
Materials & Methods

Subjects
Serum samples were obtained from consenting, Caucasian, non-diabetic, female subjects (age 42.3±16 years (mean±SD); BMI 29.8±5.4 Kg/m 2 (mean±SD) n=26). Arterio-venous difference studies were undertaken on 18 of the subjects All subjects were weight-stable for at least 2 months prior to the study, and were considered to be in good health, after completing a comprehensive medical evaluation including history and physical examination, blood tests and electrocardiogram. All subjects were taking no regular medication and premenstrual female subjects were studied during the follicular phase of their cycle. All obese subjects had been weighed regularly prior to the study. Commercially available ELISA based colorimetric kits were used to examine levels of ANG II and TNFα in the thawed serum samples (Phoenix Pharmaceuticals, USA and R&D Systems UK, respectively).
Abdominal subcutaneous adipose tissue blood flow was evaluated using the 133Xe washout technique (18, 19) . 40-50 mCi of 133Xe dissolved in 0.1 ml of saline was slowly injected over 60 seconds into the subcutaneous abdominal adipose tissue space. The decline in 133Xe was monitored continuously from 60 to 120 min after injection with a sodium iodide scintillation detector set to measure the 81 keV 133Xe photopeak.
Tissue Culture
In brief, 10-20g wet weight fresh abdominal subcutaneous adipose tissue was collected.
Tissue was initially washed with 1X Hank's balanced salt solution (HBSS) containing penicillin (100U/mL) and streptomycin (100μg/mL). Visible blood vessels and connective tissue were removed and the tissue finely chopped. All adipose tissue was digested with the same batch of collagenase class 1 (2mg/mL, Worthington Biochemical Corporation) in 1X
HBSS (Gibco, UK) for 1 h at 37 o C in a water bath and shaken at 100 cycles/min at 37 o C (20) .
The disrupted tissue was filtered through a double-layered cotton mesh and pre-adipocyte cells and adipocytes separated by centrifugation at 360g for 5 min.
Mature Adipocyte Isolation
Following centrifugation, the upper layer of mature adipocytes was removed from the collagenase-dispersed preparation, washed in phenol red-free medium DMEM:F12 twice and centrifuged at 360g for 2 min. Adipocytes were then cultured in flasks (25cm 2 ) in phenol-red free Dulbecco's modified Eagle's (DMEM:F12) medium containing 15mmol/L glucose, penicillin (100units/mL) and streptomycin (100μg/mL)). Aliquots of 1mL containing approximately 500,000 mature adipocytes were maintained in medium (5mL) per 25cm 2 flask
for 48 h and treated once with insulin alone (1-1000nM; Sigma UK) insulin in combination with RSG, (Ins: 1nM-1000nM & RSG 10nM), RSG alone (10nM) and TNFα (10ng-100ng)
for 48 h. Adipocytes maintained in untreated medium for 48 h were used as controls.
Following incubation of adipocytes (37 o C/5%CO 2 ) with their respective treatments, the conditioned media and adipocytes were separated by centrifugation (360g for 2 min). The media were then removed, aliquoted and stored at -70 o C.
Protein Assay
Following removal of the conditioned media, 4% SDS was added to the adipocytes. Adipocyte protein samples were assessed to determine that there was no significant statistical variation between control and treatment regimens, indicating secretion of ANG II was not due to adipocyte protein variation between samples.
Western Blotting
Western blot analysis was performed using a method previously described (23). In brief, min. Autoradiographs were quantified by densitometry using a Gelbase/Gelblot programme (UVP Ltd, UK).
ANG II, Bradykinin and TNFα Assays
Secreted ANG II, bradykinin and TNFα levels from abdominal subcutaneous adipocytes were determined. For this, stored conditioned medium samples were thawed and commercially available ELISA based colorimetric kits were used to determine the quantities of ANG II, bradykinin and TNFα secreted from adipocytes (Phoenix Pharmaceuticals, USA;
Bachem, UK and R&D Systems UK, respectively).
Statistical analysis
For assessment of protein expression and secretion, statistical analysis was undertaken using ANOVA for comparison of control versus treatments. The threshold for significance was p<0.05. Data in the text and figures are presented as mean ± SD or mean ± SEM. SPSS version 12 was used to examine correlations.
For comparison of arterial and venous drainage for each subject, data were analysed using a paired t-test. Correlations were determined using a Pearson correlation. All statistics were performed on SPSS, version 12. 
Results
Subcutaneous Abdominal Adipose Tissue Production of ANG II
Correlation Between Plasma ANG II Levels and BMI
Increasing BMI showed a positive correlation with increasing circulating ANG II levels in these subjects (age 42.3±16 years (mean±SD); BMI 29.8±5.4 Kg/m 2 (mean±SD) n=26; r 2 = 0.142; p=0.057, Figure 1 ), although this was not significant. ANG II levels from subcutaneous venous drainage showed no correlation with increasing BMI (data not shown). Increasing BMI also showed a significant positive correlation with increasing diastolic blood pressure ((r 2 =0.414; p<0.01, data not shown). However, no such association was observed with systolic blood pressure (data not shown).
Correlation Between Venous Adipose Tissue TNFα and ANG II Levels
TNFα and ANG II from subcutaneous adipose tissue venous drainage demonstrated a significant positive correlation with increasing levels (r 2 =0.491; p<0.01**, Figure 2 ).
The Effect of Insulin and Insulin with RSG on Secretion of TNFα
In 
The Effect of TNFα on AGT Protein Expression
Western blot analysis confirmed a concentration dependent increase in AGT protein expression in subcutaneous adipocytes treated with increasing concentration of TNFα compared with control (Control: 1± 0.0; (mean ± SE), 3.7± 0.5, p<0.001*** at 100ng TNFα, Figure 4 ).
The Effect of TNFα on ANG II Secretion
Human subcutaneous abdominal adipocytes treated with TNFα for 48h showed a concentration dependent increase in ANG II secretion with maximal stimulation at 100ng
TNFα compared to control (Control: 237.0± 52; (mean ± SE), TNFα 100ng: 398±61 pg/mL, p<0.05*; Figure 5 ).
The Effect of Insulin in Combination with RSG on AGT Protein Expression
Western blot analysis demonstrated that the presence of the insulin sensitiser, RSG, significantly reduced the insulin-mediated increase in AGT protein expression at all concentrations of insulin (Control: 1.0±0.0; (mean±SE), protein expression measured relative to control; Ins 1nM: 2.64±0.32↑***; Ins 10nM: 3.52±0.48↑***, 100nM Ins: 4.37±0.57↑***;
1000nM Ins: 6.50±0.97↑***; p<0.001***; Figure 6 ).
The Effect of Insulin and RSG on ANG II Secretion
ANG II secretion was regulated by insulin in a concentration dependent manner, with maximal stimulation occurring at 1000nM (Figure 7 ). However, in the presence of RSG the insulin mediated rise in ANG II secretion was significantly reduced at all insulin concentrations (p<0.001***; Figure 7 ). RSG alone (10nM) significantly reduced ANG II secretion compared to control, (Control: 214.33±(SEM)12.34 pg/mL; RSG: 104.44±14.35pg/mL, p<0.01; data not shown).
The Effect of Insulin and Insulin with RSG on Bradykinin Secretion
Subcutaneous abdominal adipocytes treated for 48 h showed no significant change in bradykinin secretion with insulin treatment (1nM-100nM) or insulin (1-100nM) in combination with RSG (10nM) (Data not shown). RSG alone (10nM) did not alter bradykinin secretion (data not shown).
Discussion
Many studies have implicated a role for the adipose tissue RAS in the development of obesity associated hypertension. Rodent studies comparing blood pressure levels in obese Zucker rats versus genetically lean Zucker rats have shown that blood pressure is significantly higher in the obese rodents. Furthermore, the administration of an ANG II receptor antagonist to these animals significantly lowered blood pressure, thus demonstrating that ANG II contributes to the elevated blood pressure observed in these animal models (24) . However, studies by Faloia
and colleagues did not demonstrate a difference in circulating components of the RAS between obese hypertensive, obese normotensive subjects and lean controls (25) . Our findings indicate a positive correlation between increasing BMI and circulating ANG II levels, although this was not significant. The present study also revealed a positive association between BMI and diastolic blood pressure, whilst systolic blood pressure exhibited no correlation with BMI. These findings support the association between obesity, hyperinsulinaemia, increased ANG II production and elevated blood pressure. Furthermore, in addition to its' systemic effects, recent studies have highlighted the importance of resistance vessels within adipose tissue depots with regard to hypertension. Both structural and functional abnormalities have been identified in arterial resistance vessels extracted from adipose tissues depots in type 2 diabetic and hypertensive patients (26, 27) . Therefore the local RAS may also be acting in a paracrine fashion to have a significant effect on blood pressure, as well as being a potential mediator in the observed vascular remodeling of these vessels.
Whilst the positive correlation between obesity and hypertension is apparent, the molecular mechanisms that underlie its' pathogenesis remain unclear. Hypertension and hyperinsulinaemia/insulin resistance form part of the diagnostic criteria for the metabolic syndrome, a condition that is strongly associated with obesity. We have previously investigated the effect of increasing insulin concentration on the RAS in subcutaneous human adipocytes and subsequently demonstrated that insulin concentration increases both expression and secretion of AGT and ANG II, respectively (7) . These data suggested that chronic exposure to elevated insulin levels might induce upregulation of the RAS in subcutaneous adipocytes, thus proffering a potential mechanism mediating obesity associated hypertension. Furthermore, the importance of the RAS pathway is not limited to hypertension as ANG II, the effector molecule in the pathway, has also been identified as a proinflammatory factor. Studies have shown that it activates expression of early response and inflammatory genes in vascular smooth muscle cells (28, 29) and regulates the production of PAI-1, which inhibits fibrinolysis (4). Obesity is associated with a state of sub-clinical inflammation so the pluripotent nature of ANG II has implications for other facets of the condition. Therefore, understanding the mechanisms through which AGT and hence ANG II are regulated may provide additional insights into the pathogenesis of the metabolic syndrome and new approaches to reducing the risk of cardiovascular disease.
In the present study we have demonstrated that subcutaneous adipose tissue is a significant site of AGT and angiotensin II production via arterio-venous measurements and through in vitro protein studies. Previous rodent studies have indicated the importance of adipose tissue RAS as contributing to plasma levels of AGT and ANG II, but no study to date has examined the importance of subcutaneous, abdominal, human adipose tissue (30) . Our findings revealed a significant increase in ANG II levels in the subcutaneous abdominal adipose tissue effluent of 23% (p<0.001), thus affirming the relevance of studying this tissue with regard to obesity associated hypertension.
We also determined that insulin did not influence bradykinin secretion. Consequently, the possible mechanisms through which insulin increased AGT, and hence ANG II protein secretion, were examined. A potential mechanism for regulation of adipose tissue RAS was suggested by the observation that, in hepatocyte cells, the AGT promoter contains a cytokine inducible enhancer known as the acute phase response element (APRE) (11) . One cytokine known to induce transcription of AGT is TNFα -a multifunctional cytokine produced by a variety of cells that include monocytes/macrophages, muscle cells and adipose tissue (11) .
TNFα is implicated as a pathogenic factor in the development of obesity-associated insulin Previous data have demonstrated that rosiglitazone (RSG) reduces blood pressure in animal models, type 2 diabetics and obese patients (12) (13) (14) (15) (16) . RSG has been shown to reduce oxidative stress, thus ameliorating endothelial dysfunction and improving blood vessel elasticity (31).
However, no study to date has examined the effects of RSG on the RAS in human adipocytes and obesity associated hypertension. Our present study showed that the introduction of RSG into this system dramatically reduced the insulin-mediated effect on the RAS. This is an interesting finding as the insulin sensitising action of RSG, through transactivation of responsive genes, would suggest that AGT and ANG II would increase further in the presence of this agent. These findings, however, are in accord with in vivo data, with RSG inducing downregulation of TNFα and the RAS in adipocytes, in vitro. In addition, RSG also negated the insulin mediated increase in TNFα secretion, further supporting the possibility of a TNFα regulated effect on the RAS. However, the effects of insulin and RSG were limited to the vasoconstrictive pathway in the RAS cascade, as bradykinin secretion remained unaltered by insulin in the presence of RSG.
In conclusion, exposure of adipose tissue to a hyperinsulinaemic environment may produce increased ANG II through the actions of TNFα, which is also elevated in obese and type 2 diabetic subjects (7). Our findings demonstrate the potential of this mechanism and the contributory role that the adipose tissue RAS may have in obesity associated hypertension.
RSG mitigates the insulin mediated increase in the adipose tissue RAS and therefore this finding may help to explain the long-term anti-hypertensive effects of RSG. RSG has already been shown to improve endothelial dysfunction and hence may offer additional benefits in terms of the adipose tissue RAS (31) . As yet, it remains unclear as to how RSG is producing its' effects. Within liver cells it is apparent that the TNFα mediated induction of AGT involves the nuclear transcription factor NFκB -a protein linked to the regulation of many pro-inflammatory cytokines (11) . This pathway has not been examined in the adipocyte with regard to the RAS. It may be the key transcription factor involved in this pathway and therefore requires further investigation. Table 1 . The individualised subject data points of arterial and venous drainage and the net arterio-venous concentration differences for ANG II, as well as the mean ± SD for each grouping (n=18, p-value: p<0.001***). p<0.001***
